SEC For	rm 4																		
FORM 4			UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549													OMB APPROVAL			
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).			STA		AT OF CHANGES IN BENEFICIAL OWNE d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									HIP	Estin	OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
1. Name and Address of Reporting Person [*] Bellon Steven F.					2. Issuer Name and Ticker or Trading Symbol <u>Foghorn Therapeutics Inc.</u> [FHTX]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify				wner	
	(Last) (First) (Middle) 500 TECHNOLOGY SQUARE STE 700				3. Date of Earliest Transaction (Month/Day/Year) 01/26/2023									A below) below) Chief Scientific Officer					
(Street) CAMBR	RIDGE M	02139		4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City) (State) (Zip)																			
Table I - Non-Deriv 1. Title of Security (Instr. 3) 2. Trans Date (Month/I)							a, 3. 4. Securi Transaction Disposed Code (Instr.			of, or Beneficia rities Acquired (A) or od Of (D) (Instr. 3, 4 a			5. Amour	s Illy ollowing	Form (D) or	r Indirect I str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code V	′	Amount		(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)				(1150.4)	
								uired, Dis s, options						Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate, Tra Co	e, Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securitie Benefici Owned Followin Reporte	ve es ally Ig d	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Co	de V	(A)	(D)	Date Exercisable		xpiration ate	Title		Amount or Number of Shares]	Transaction((Instr. 4)				

Explanation of Responses:

\$8.38

1. The option vests as to 25% of the underlying shares of common stock on January 26, 2024, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.

(1)

100,000

Remarks:

Stock Option (right to buy)

> /s /Allan Reine, M.D., Attorney-01/30/2023

\$0.00

100,000

D

in-Fact

Common

Stock

01/25/2033

** Signature of Reporting Person Date

100,000

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

01/26/2023

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Α

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.